Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | garadacimab | Hereditary angioedema (HAE) | Active | |||
TBC | delgocitinib | Chronic hand eczema | Pending | |||
TBC | rozanolixizumab | Generalized myasthenia gravis (gMG) | Active | |||
TBC | dabrafenib-trametinib | Pediatric low grade glioma (ped LGG) | Active | |||
TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Active | |||
TBC | crovalimab | paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
TBC | teprotumumab | Thyroid Eye Disease (TED), acute | Received | |||
TBC | teprotumumab | Thyroid Eye Disease (TED), chronic | Received | |||
TBD | Cabozantinib | Withdrawn | ||||
TBD | Rituximab | Cancelled |